|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Comprehensive
side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7(8):633-43. Abstract
Barrett-Connor E et al; Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355(2):125-37. Abstract
Coleman RE et al. Effect of anastrozole on bone mineral density: 5-year results from the ‘Arimidex,’ Tamoxifen, Alone or in Combination (ATAC) trial. ASCO
2006;Abstract 511.
Cuzick J et al. Long-term results of tamoxifen prophylaxis for breast cancer — 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99(4):272-82. Abstract
Cuzick J et al. Long term efficacy of tamoxifen for chemoprevention — Results of the IBIS-I study. San Antonio Breast Cancer Symposium 2006;Abstract 34.
Gnant MF et al. Zoledronic acid effectively prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group J Clin Oncol 2007;25(7):820-8. Abstract
Gnant M et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen — Bone density subprotocol results of a randomized multicenter trial (ABCSG-12). San Antonio Breast Cancer Symposium 2004;Abstract 6.
Gradishar W et al. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: First results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 12.
Howell A et al. Analysis of fracture risk factors from the ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: 5-year data. Proc ASCO 2006;Abstract 563.
Jenkins V et al. Preliminary results from the IBIS II (prevention) cognitive sub-protocol. San Antonio Breast Cancer Symposium 2006;Abstract 5076.
Powles TJ et al. 20 year follow-up of the Royal Marsden tamoxifen breast cancer prevention trial. San Antonio Breast Cancer Symposium 2006;Abstract 51.
Sestak I et al. Comparison of side-effect profiles during active treatment versus followup in the IBIS-I tamoxifen prevention study. San Antonio Breast Cancer Symposium 2006;Abstract 1051.
 |
 |
